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Abstract: Fused filament fabrication (FFF) 3D printing technology is widely used in many fields.
For almost a decade, medical researchers have been exploring the potential use of this technology
for improving the healthcare sector. Advances in personalized medicine have been more achievable
due to the applicability of producing drug delivery devices, which are explicitly designed based on
patients’ needs. For the production of these devices, a filament—which is the feedstock for the FFF 3D
printer—consists of a carrier polymer (or polymers) and a loaded active pharmaceutical ingredient
(API). This systematic review of the literature investigates the most widely used approaches for
producing drug-loaded filaments. It also focusses on several factors, such as the polymeric carrier and
the drug, loading capacity and homogeneity, processing conditions, and the intended applications.
This review concludes that the filament preparation method has a significant effect on both the drug
homogeneity within the polymeric carrier and drug loading efficiency.
Keywords: hot melt extrusion; additive manufacturing; fused filament fabrication; fused deposition
modeling; 3D printing; drug loading; drug delivery
1. Introduction
In the 1980s, the process of layer manufacturing was established in Japan, France, and the
US [1]. This manufacturing method is similar to the contour maps; i.e., each three-dimensional
model is sliced into two-dimensional sections along its height [2]. Subsequently, these layers are
3D printed, one after another, until the complete geometry is produced. One of the first additive
manufacturing (AM) machines used stereolithography technology, which was introduced by 3D
systems [3]. Since then, several techniques have been introduced such as, selective laser sintering,
laminated object manufacturing, fused deposition modeling (FDM™), and others [4]. In the medical
field, AM shows great potential [5]. One of the greatest advantages of AM is the capability of producing
patient-specific products in a short lead time. An example of 3D printing technologies that have already
introduced novel drug delivery systems to the market is “Spritam®”. This system was developed by
Aprecia Pharmaceuticals and was approved by the Food and Drug Administration in 2015. This drug
delivery system is produced using the Zipdose® technology, which relies on a powder bed liquid
3D printing approach [6]. The presented system is a high dosed tablet with rapid disintegration
capabilities [7].
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FDM™, also known as fused filament fabrication (FFF), is a widely used technology. It has
exhibited a considerable reduction in price during the last decade. This technology also has many
advantages compared to other 3D printing technologies, such as being user-friendly with minimal
post-processing steps for the end-product. In a standard FFF 3D printer, a filament is melt-extruded
through a nozzle with a specific diameter that moves in three-dimensional space in a controlled manner
to build a 3D geometry. Upon heating, the physical state of thermoplastic polymers changes from
solid to semi-solid up to liquid when fully melted. The suitable printing temperature depends on the
thermal properties of the polymer and the rheological properties of the melt [8].
The filament is usually prepared via the hot melt extrusion (HME) process, which is a
well-established technology used for processing polymers. This technology is used for producing
different types of products. In principle, HME relies on the change in the physical properties of the
materials upon heating. This technology uses a screw-based extrusion system located in a barrel and
is driven by a motor. After the explosion of the FFF market in the past decade, the HME technology
was heavily used to produce the feedstock material for these 3D printers, which is in the form of a
filament with a diameter ranging between 1.75 mm and 3.00 mm. Many process parameters and
material characteristics have been explored and investigated to provide the market with different types
of materials that can serve various applications [9].
Over the past years, numerous reviews have been published that discuss the used of AM
technologies for the production of drug delivery systems, such as Hsiao et al. [10] and Korte et al. [11].
Other studies have focused on FFF 3D printing technology, such as Araujo et al. [12] and
Mathew et al. [13]. A recent review by Azad et al. [14] discussed various polymers used in such
processes and the material properties that should be considered when developing a drug-loaded
device. However, none of these reviews or studies provided a detailed discussion of the various
techniques and methods that are used for producing a drug-loaded filament. As these techniques
vary among researchers, the quality of the produced filament greatly depends on the method used.
Additionally, the loading efficiency and homogeneity of the drug within the filament will also greatly
affect the efficacy of the produced drug delivery system. Thus, this systematic review focuses on
discussing the various drug incorporation approaches into a carrier polymer for producing filaments
used for the FFF 3D printing process. Moreover, polymer and drugs that were used in these studies are
summarized, along with their intended application.
2. Methods
This systematic review was based on the PRISMA guidelines [15]. Two electronic databases
(WebofKnowledge and PubMed) were used to survey the literature. The keywords selected for this
review were divided into two parts. First, fused filament fabrication, fused deposition modeling,
FDM™, and FFF; the most used terms that refer to the AM technology under investigation in this
review and the most widely used acronyms for this technique. Secondly, drug delivery and drug
loading; these two keywords were selected to limit the results from publications related to drug loading
applications. This was required as the FFF process has a variety of applications in many different fields
such as aerospace, architecture, and product development.
The search phrase in the WebofKnowledge was “(TOPIC: (fused filament fabrication) OR TOPIC:
(fused deposition modeling) OR TOPIC: (FDM) OR TOPIC: (FFF)) AND (TOPIC: (drug delivery)
OR TOPIC: (drug loading))” and in the PubMed was “(((drug delivery) OR drug loading)) AND ((((fused
filament fabrication) OR fused deposition modeling) OR FDM) OR FFF).”
In this review, a selection of criteria was designated for determining which articles were to be
included. These were (1) the drug should be incorporated into the polymer’s matrix prior to 3D
printing, (2) carrier polymers should be a thermoplastic polymer, and (3) 3D printing technology
used should be FFF technology. Additionally, only original research articles were included, and other
publications such as conference papers, review articles, etc. were excluded.
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There was a specific focus on several key topics during the data extraction process. Among these
topics were (1) carrier polymer; (2) loaded drug; (3) drug loading percentage, which is defined as the
percentage of loaded drug mass relative to the total mass of system; (4) drug loading efficiency, which is
defined as the percentage of the measured drug in the produced filament or 3D printed device relative
to the theoretical loaded drug; (5) processing temperature; (6) drug loading approach; (7) 3D printer
used; (8) intended application; and (9) produced samples.
3. Results and Discussion
3.1. Literature Search Output
As shown in the Supplementary Material (Figure S1), the search engines resulted in 235 and
145 articles from WebofKnowledge and PubMed, respectively. The digital object identifier system
was used to exclude duplicates from the results, which resulted in 267 articles. Finally, titles and
abstracts were screened to remove irrelevant articles based on the criteria mentioned in the methods
section. The excluded articles were 207, which revealed 60 articles to be included in this systematic
review. Moreover, it was noted that the interest in this topic has increased over the years, as shown
by an increase in the number of published articles. As demonstrated in Figure 1, only one paper
was published in 2011, while 19 papers were published in 2019. All the data gathered from these
publications are summarized in the Supplementary Material (Table S1).
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the size between the polymer and the drug can be a major cause of an inhomogeneous drug 
distribution in the produced filament [16]. Thus, a pre-step of milling and sieving is required to 
reform the polymer or polymers. However, this step is not essential for other techniques such as 
solvent casting. This is because the polymer is typically dissolved in an organic solvent. On the other 
hand, the drug can be either dissolved or suspended. Subsequently, a stirring step is performed that 
enables the homogenization of the mixture. Finally, the last step includes the production of filaments. 
This can be done using different approaches, which will be discussed later in this review. The 
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Figure 1. r f lic ti s i cl e i t is revie over the years.
3.2. Drug Loading Approaches
In all the selected articles in this review, the process for producing a drug-loaded medical
device was conducted by preparing a filament which consists of carrier polymer/s and loaded
drug/s. Subsequently, this filament is loaded into an FFF 3D printer by which the device is produced.
According to the selected articles, an initial step might be required if the polymer’s form is incompatible
with the drug. This is generally done when the polymer is supplied in the form of pellets or
chips, while drugs are mostly supplied in a powdered form. In processes such as physical mixing,
homogenizing in the extruder before extrusion, and melt-blending (see Figure 2), a large variation
in the size between the polymer and the drug can be a major cause of an inhomogeneous drug
distribution in the produced filament [16]. Thus, a pre-step of milling and sieving is required to reform
the polymer or polymers. However, this step is not essential for other techniques such as solvent
casting. This is because the polymer is typically dissolved in an organic solvent. On the other hand,
the drug can be either dissolved or suspended. Subsequently, a stirring step is performed that enables
the homogenization of the mixture. Finally, the last step includes the production of filaments. This can
be done using different approaches, which will be discussed later in this review. The different steps
and approaches are illustrated in Figure 2.
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sequently, the filament that contai s the carrier polymer is soaked and conditioned in the prepared
system for a c rtain period of time to assure diffusion into the polym ric matrix. It is worth noting
that only one publication stated preparing a dis ersion system [18], while all other publications t at
used this appro ch prepared a solution system. This method greatly depends on the swelling of the
polymers when submerged in certain olvents. The time needed for prop r sw lling of the filament
greatly affects the drug loading [19]. T soaking uration can vary between 12 h, as reported by
Qamar et al. [20] up to 3–4 d ys, as rep rted by Ibrahim et al. [21]. In this process, a commercial
filament can be used, which is the main advantag of this appro ch. However, this process has many
d awbacks as it uses solvents that might be toxic. Additionally, the drug l ading capacity is very
limited and highly dependent on the iffusion kinetics between the drug and th polymeric m trix in
the solvent/dispersion system. As een in Figure 4A, the maximum drug loading capacity reporte in
the publicati ns included in this review was 5% (w/w). This proces is not eco-friendly due to the large
portion of wasted drugs in the solution/dispersion. Moreover, the industrialization of this method can
be relatively challenging.
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3.2.2. Single Screw Extruder
In the single screw extrusion configuration, as shown in Figure 3A, a single rotating screw is used
to generate the flow of material. This screw contains three sections—(1) feeding, (2) compression,
and (3) metering section [22]. The material is fed from a hopper in the feeding section. Then, it melts
via shear stress and/or heating elements along the compression and metering sections. Finally, it flows
out of a well-defined nozzle. In this approach, the drug and the carrier polymer should be sufficiently
mixed before feeding to the extruder to assure optimum homogeneity of the output mixture. This is
vital, as the single screw extrusion process provides limited homogenization of the mixture during
extrusion. In addition, drugs are typically provided in a powdered form. However, polymers can
exhibit several forms, ranging from small particles up to pellets or chips, which can significantly affect
the homogeneity of the mixture [16]. Thus, an earlier step such as grinding and sieving, as illustrated
in Figure 2, is required for obtaining the polymer in a suitable form. Once a suitable particle size is
achieved, several mixing approaches were used in the reviewed articles, such as mixing in a container
using an automatic mixer or mixing using a mortar and pestle. On the other hand, other approaches
that do not require the polymer preparation stage, such as solvent casting or melt blending were used
in other studies [23–27]. The former process includes the use of solvents to dissolve the polymer
with the loaded drug. The latter process involves melting the polymer and homogenizing it with the
drug before extrusion. The preparation of the physical mixture of the polymers and the drugs prior
to extrusion is crucial as poor mixing could result in non-homogeneous blending, which will affect
the content uniformity of the final product. An example of non-ideal extrusion was illustrated by
Goyanes et al. [28] and Long et al. [29]. The drug loading in the extruded sample was around 80%
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and 70% of the theoretical value, respectively. This was due to adhesion of powdered drug particles
to the walls of the container, including the hopper and the barrel during extrusion using a single
screw extruder.
3.2.3. Double Screw Extruder
In the double screw extruder, as shown in Figure 3B, a variety of configurations can be used.
Generally, a co-rotating or counter-rotating double screw with an intermeshing or non-intermeshing
setup is used [22]. This system has several advantages over the single screw extrusion system, such as
an improved mixing that enables the production of a more homogeneous output, as illustrated by
Patil et al. [30]. Additionally, lower shear stresses compared to single screw extruders are applied,
which is essential during the extrusion of sensitive drugs. Another important advantage in this system
is self-cleaning during extrusion. When the two screws are placed in an intermeshing configuration, the
flight of one screw can remove the material in the root of the other one [6]. It was noted that 50% of the
reviewed articles used this approach for the production of feedstock filaments due to its better mixing
capabilities. Moreover, it was noted that some publications provided fewer details when describing
the premixing method before extrusion, such as Isreb et al. [31], Sadia et al. [32], Okwuosa et al. [33,34],
and Pietrzak et al. [35]. These publications described a melt mixing step in the extruder for around
5–10 min before starting the extrusion process. Additionally, Hollander et al. [36] used a similar melt
mixing step before extrusion. However, this research group added 1/5 of the polymer amount, and
then the drug and subsequently the remaining polymer to the extruder. Finally, a melt mixing step of
10 min was performed. This resulted in a drug loading efficiency of 83%, which was the lowest in this
approach. During this mixing period, the extruder was set to temperatures suitable for melting the
mixture. Moreover, other research groups used a mixer or mortar and pestle for homogenizing the
mixture before feeding it to the extruder. Generally, the double screw extrusion configuration resulted
in a drug loading efficiency ranging from 83% [36] to 100%. Furthermore, this process did not differ
from the single screw extrusion in terms of drug loading capacity, as the maximum loading percentage
reported among the reviewed articles was 60% (w/w), as described by Verstraete et al. [37].
3.2.4. Other Approaches
Few articles used other processes for the preparation of the filaments. For producing drug-loaded
filaments, one method used a piston extruder in which a piston was used to push the melted material
through a well-defined nozzle. This technique was shown by Kempin et al. [17,38] and Teo et al. [27].
Another approach used a melt blender to create a homogenized blend of the polymer and the drug.
Then the melt was cast in a tube with a desired diameter [39]. In these studies, the materials were
premixed using a mortar and pestle or a mixer.
It was noted that more than 80% of the publications considered for this review used a single screw
or double screw extruder to produce the filament for 3D printing. This is due to the well-established
knowledge related to the HME process used in the pharmaceutical industries. Figure 4A summarizes
the drug loading capacity based on the technology used, which was between 1% and 60% (w/w) in the
single and double screw extrusion system. These two methods provide wide flexibility in terms of
drug loading capacity, taking into consideration the limitation in drug homogeneity in the single screw
extrusion process. A major cause of such poor homogeneity is the high pressure generated during
extrusion, even when an ideal mixture is fed to the extruder. This pressure may compress the dispersed
particles in the melt and can generate agglomerates which will affect the homogeneity of the mixture [6].
The filament soaking approach was discussed in several publications. However, it showed a limited
capability in terms of the drug loading capacity, even with a long soaking duration, as demonstrated
by Ibrahim et al. [21], in which the loading percentage ranged from 0.3% up to 5% (w/w). This could be
due to the limited diffusion of drugs into the polymer matrix, as the diffusion is highly dependent on
the polymer swelling. However, it should be noted that extensive swelling might cause significant
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deformation of the filament, which will result in inconsistencies in the diameter of the filament after
drying. This could cause problems during 3D printing.
Filaments produced using other mixing approaches were mostly extruded using a piston
extruder. This method has similar flexibility in the drug loading capacity to screw extrusion processes.
However, the drug–polymer mixture homogeneity totally relies on the premixing process before the
extrusion. This is due to the lack of material homogenizing during the extrusion process. Most of the
publications included in this review that used a piston extruder reported that a homogenized system
was prepared before the extrusion process via a pre-melt mixing step.
Figure 4B compares the drug loading efficiency in the single and double screw extrusion system.
This comparison excluded the filament soaking approach, as most studies focused on reporting the
percentage of drug that was loaded into the filament and not the loading efficiency. This is because
the percentage of the remaining drug in the solution/dispersion system was not always discussed
and the focus was only on measuring the percentage of the drug loaded into the filament. As shown
in Figure 4B, 10 out of 18 and 13 out of 31 publications discussed the drug loading efficiency of
the produced filaments using single screw or double screw extrusion, respectively. The variation
in the drug loading efficiency reported in the single screw extrusion ranges between 65% and 100%
of the total percentage of loaded drug. This significant variation can be due to poor mixing using
this configuration. Furthermore, the homogeneity of the drug among the polymeric matrix mostly
depends on the premixing method used prior to extrusion. Long et al. [29] directly extruded the
polymer pellets and the drug using the single screw configuration. Subsequently, the produced
filament was grinded and re-extruded. However, the drug loading efficiency in this approach ranged
between 70% to 90%. Mixing the polymer and the drug in the powdered form using mortar and
pestle, mixer or by manual shaking in a container yielded large variations in loading efficiency, as the
process is highly subject to human error. This was observed by Gultekin et al. [40], Li et al. [41],
and Goyanes et al. [28,42,43] where the drug loading efficiency was 96–100%, 88–96%, and 82–97%,
respectively. On the other hand, smaller variations are observed in the double screw extrusion system,
as the drug loading efficiency reported for double screw extruders ranged between 83% and 100%.
The lower variation in drug loading efficiency demonstrated the superiority of homogenizing the
mixture within a double screw extruder.
3.3. Carrier Polymer and Drugs Used
The carrier polymer plays two critical roles in the drug loading process. On the one hand,
it is the medium in which the loaded drug is stored before it is released. On the other hand, it
should provide the required mechanical properties to satisfy the requirements for extrusion and 3D
printing. Moreover, the processing of this carrier polymer from raw material to end-product should
not compromise the APIs’ activity. Selecting suitable temperatures for the process depends on many
parameters, such as the physical properties, the melt rheology and the degradation temperatures of
the ingredients due to the heat sensitivity of some drugs [44]. An example of a drug’s degradation
during processing was reported by Goyanes et al. [26], in which salicylic acid was degraded during
extrusion and the measured drug was only 30% of theoretical loaded drug. Moreover, it is vital to reach
a suitable extrusion temperature to ensure the proper flow of material during filament preparation
or 3D printing. Generally, temperatures needed during filament preparation are lower compared to
3D printing. This is due to the high torque achieved in a single or a double screw extrusion system.
However, during 3D printing, a higher temperature is needed to achieve the required viscosity and
ensure optimum material flow.
The processing temperatures observed in the publications considered for this review were classified
into three categories, namely, (1) less than 100 ◦C, (2) between 100 ◦C and 150 ◦C, and (3) More than
150 ◦C. Figures 5 and 6 illustrate the polymers used and APIs based on these three categories,
respectively. Around 10% of the reviewed publications used temperatures below 100 ◦C. One study
used oleo-gum resins from benzoin, which were loaded with metal oxide and 3D printed at 60 ◦C [45].
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Concomitantly, another research group discussed the applicability of 3D printing at low temperatures
to incorporate thermolabile drugs such as ramipril [46]. In this study, drug-loaded Kollidon®
VA64 and 12 PF were 3D printed at 90 ◦C. Moreover, other researchers used polyethylene glycol
6000 and Kollidon® 12 PF to load pantoprazole sodium and 3D print at around 54 ◦C and 79 ◦C,
respectively [17]. Furthermore, polycaprolactone was used to load gentamycin sulfate and print at a
temperature of 100 ◦C [27]. Around 17% of publications used in this review used medium processing
temperatures between 100 ◦C and 150 ◦C. Costa et al. [47] mixed poloxamine and polycaprolactone to
load dexamethasone. The mixture was 3D printed at 110 ◦C. Sadia et al. [48] prepared a mixture of
Eudragit® E, triethyl citrate, and tri-calcium phosphate and used hydrochlorothiazide as the loaded
drug and 3D printed the produced filament at 135 ◦C. In contrast, 73% of the reviewed publications
performed printing at temperatures higher than 150 ◦C. The highest processing temperature was
reported by Tagami et al. [39]. In this study, a polyvinyl alcohol filament was loaded with curcumin as
a model drug, which was 3D printed at a temperature range of 150 ◦C to 250 ◦C. However, a change in
color was reported in the produced samples as the processing temperature increased, which resulted
in the degradation of the drug. The measured drug concentration was decreased to 79% (w/w)
at 150 ◦C and 15% (w/w) at 250 ◦C. Moreover, in a study by Farto-Vaamonde et al. [49], prednisolone
and dexamethasone were loaded into polylactic acid filaments using the filament soaking approach.
Subsequently, the drug-loaded filaments were printed at 220 ◦C. Zhang et al. [50] investigated the
possibility of coupling 3D printing with HME by testing different formulations of carrier polymers.
Acetaminophen was used as a model drug in combination with several polymers, such as Benecel™
HPMC E5, Klucel™ HPC, Aqualon™ EC N14, Soluplus®, and Eudragit® L100. Filaments from
different formulations were extruded at a temperature range between 140 ◦C to 160 ◦C and 3D printed
at 200 ◦C. In this study, no drug degradation was reported as 100% of the drug was released within 24 h.
The intended application is a key player in the selection of the carrier polymer for the drug-loaded
device. Moreover, the properties of this polymer will determine the efficacy of the system. In some
applications, such as orthopedics, high mechanical properties are required. Most often, a polymer with
high mechanical properties, such as polylactic acid, requires high processing temperatures. This can be
very challenging when the loaded drug is thermally labile.
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Moreover, another challenge is the 3D printing process. Unlike HME, it is not a continuous
process, this is due to repeated interruptions in the extrusion process during printing and non-printing
movements. This could cause a longer exposure to high temperatures, which can lead to ore
degradation of the loaded drug. Thus, it is very i portant to take into account all the conditions that
the drug ill endure during the HME and the 3D printing process and to select a carrier polymer
based on these considerations to ensure the efficacy of the drug-loaded system that is produced.
3.3.1. 3D Printing of Drug-Loaded Devices
After the expiration of the Strata ys patent [51] and the establish ent of th Reprap open-source
soci ty [52], the number of fused filament fabr cation 3D printers has rapidly increased. The relatively
low price of these printers has enabled further research to investigat their applicability for producing
drug-l aded medical devices. Figure 7A illustrates the 3D printers us in the selec ed a ticles. It was
noted that the Makerbot Replicator 2X is the most widely used 3D printer, as more than 50% of the
publicatio s included in this review used it.
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3.4. Intended Application
A wide variety of applications were covered by the publications considered for this review.
These applications are illustrated in Figure 7B and were divided into the following four categories:
(1) oral drug delivery systems, (2) implants, (3) intrauterine systems, and (4) veterinary applications.
More than 75% of publications included in this review investigated the production of drug-loaded
devices for oral drug delivery. This is due to the well-established experience in HME processes to
produce oral drug delivery systems over the past years. In order to produce a printable filament,
certain physical properties should be met. One of the crucial parameters is the mechanical properties
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of these filaments to allow proper feeding into the FFF 3D printer. Thus, many researchers focused on
conducting a formulation investigation and exploration, such as Illyes et al. [53], who investigated the
printability of various formulations loaded with Carvedilol. Additionally, other research groups used
design optimization approaches for formulation selection, such as quality by design and design of
experiments such as Palekar et al. [54], Korte and Quodbach [11], and Nukala et al. [55]. The driving
system in most FFF 3D printers relies on the un-melted filament to push the melted portion and maintain
the material flow. Thus, the filament should have two main mechanical properties—(1) sufficient
strength to avoid buckling and (2) high surface hardness to avoid filament grinding caused by the
extruder gears, as shown in Figure 8A,B.
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Moreover, many research groups screened formulations to determine the drug release profile,
such as Arafat et al. [56], Goyanes et al. [57,58], Solanki et al. [59], Zhang et al. [50], Tagami et al. [39],
Alhijjaj et al. [60], Skowyra et al. [61], and Yang et al. [62]. Other groups aimed to control the drug release
profile to achieve sustained release, immediate release or a combination of both, such as Kimura et al. [63],
Gultekin et al. [40], Isreb et al. [31], and Pietrzak et al. [35]. The geometry of the tablets was thoroughly
investigated as it directly affects the release profile. Sadia et al. [48] investigated the production of
channeled tablets to accelerate drug release. Tagami et al. [64] and Gioumouxouzis et al. [65] produced
a defined drug release profile by printing a water-soluble drug-loaded material and water-insoluble
material in different configurations. Scoutaris et al. [66] explored 3D printing of tablets made from
a sweet chewable material designed to be palatable to children. Zhang et al. [67] investigated the
correlation between the release profile and the tablet geometry using mathematical models to achieve
zero-order release. Goyanes et al. [43] and Oblom et al. [68] determined the effects of different
geometries, such as a cube, sphere, cylinder, pyramid and ring, and the size of the tablet on the release
profile. Fuenmayor et al. [69] studied the difference in drug release profile between conventional
tablet manufacturing approaches, such as compression molding and injection molding, and the
new AM technology. In this study, the tablets manufactured by compression and injection molding
showed immediate and sustained release profiles, respectively. However, tablets manufactured
by FFF combined those two release profiles concomitantly. In general, 3D printing showed great
potential for producing systems with tailored a release profile. This capability was achievable by
optimizing the composition of the carrier polymer/s by combining water soluble and insoluble polymers.
Additionally, varying the shape and geometry of the produced devices also determines the release
rate of the drug. This was possible because 3D printing allows manufacturing geometries that are not
achievable through other manufacturing processes. The surface area plays a key role in this approach
for tailoring the release profile as needed.
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Drug loading capacity was also investigated by Verstraete et al. [37] and Tidau et al. [70]
as it is vital for determining the maximum drug that can be loaded into a 3D printed device.
Furthermore, Chai et al. [71] and Jamroz et al. [72] improved the solubility of poor water soluble drugs
using hot melt extrusion and investigated producing 3D printed tablets with these drugs.
Three publications studied the printing of intrauterine systems. Fu et al. [24] discussed
the production of vaginal rings loaded with progesterone using a blend of polylactic acid and
polycaprolactone. Moreover, Hollander et al. [36] and Genina et al. [73] discussed the production
of T-shaped intrauterine systems loaded with Indomethacin. Active pharmaceutical ingredients
were loaded at different weight percentages and different release profiles were achieved. One article
discussed the production of drug-loaded projectiles for veterinary application. Long et al. [29] discussed
the possibility of using 3D printing to develop progesterone loaded devices in the shape of a projectile.
The aim was to investigate the applicability of producing drug-loaded ballistic devices for drug delivery
in wildlife.
Ten articles discussed the production of implantable devices. Kempin et al. [25] and Genina et al. [73]
produced model implants using 3D printing technology for selecting and optimizing the formulations
of drug-loaded polymers. Additionally, they studied the produced material properties such as
printability, release profile and mechanical performance. Farto-Vaamonde et al. [49] and Costa et al. [47]
worked on producing drug-loaded scaffolds for tissue engineering and regeneration medicine.
Qamar et al. [20] and Teo et al. [27] produced drug-loaded meshes for eradicating bacterial infections.
Horst et al. [45] discussed producing disks for testing antibacterial activity of oleo-gum-resin loaded
with nano-oxides. Eleftheriadis et al. [74] and Jiang et al. [23] worked on producing drug-loaded devices
for oral applications such as mucoadhesive buccal films and an orthodontic retainer, respectively.
Goyanes et al. [26] discussed utilizing 3D scanning for producing a 3D model of a personalized
implant and then 3D printing it with a drug-loaded polymeric material for anti-acne applications.
It can be noted that there was only a limited focus on producing drug-loaded implantable devices.
However, the interest in these forms is increasing as there was only one publication in 2010 compared
to three in 2019. Additionally, with the continuous improvement of the FFF process, it is expected to
gain more attention in the coming years.
4. Conclusions
This systematic review discussed the drug incorporation approaches used for preparing filaments
for FFF 3D printing. A survey of 60 publications showed the differences between the preparation
techniques of filaments used in FFF 3D printing. Three methods were most widely used—(1) single screw
extruder, (2) double screw extruder, and (3) filament soaking. Fewer articles used other mixing
approaches (6% of the total review articles). The majority of the reviewed articles (50%) used double
screw extruders to prepare the feedstock filaments. This system was capable of loading a high
percentage of API with suitable filament homogeneity and minimal preparation efforts before extrusion.
The single screw extrusion system was the second most popular (30%), showing the capability of
high drug loading of around 50% (w/w). However, due to the limitation in producing homogenous
mixtures, it is vital to properly mix the materials prior to the extrusion step. On the other hand,
the filament soaking approach was the third most popular option (13%), and it is relatively simple as
commercially available filaments can be used. However, it is very limited in terms of drug loading
capacity. Additionally, a substantial portion of waste byproduct is produced with this approach.
A wide variety of polymers were used in the studies; however, it was noted that the most
significant limiting factor in choosing the material was the processing temperature. As most APIs
are thermally labile, it is vital to stay below degradation limits. Moreover, filaments should show
suitable mechanical and rheological properties to allow sufficient feeding and printing performance.
The intended application for the majority of the reviewed articles was producing oral drug delivery
systems. Other research groups discussed applications such as implant, intrauterine systems,
and veterinary applications.
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5. Future Perspectives
AM technologies show high potential for personalized medicine. Its added value can be
classified into two categories—(1) dose and formulation flexibility and (2) new possibilities in the
produced geometries. On the one hand, the concept of “production on demand” can be applied when
formulating using AM technologies. Thus, such technologies provide great potential for producing
patient-specific formulations with relatively low cost. On the other hand, coupled with 3D scanning
technologies, patient-specific devices can be produced to match the shape needed in a customized
manner. Moreover, the opportunity for creating different geometries can help to tailor the drug release
profile as required. Additionally, small-scale batch production using AM is relatively cheap compared
to conventional manufacturing technologies.
The typical approach for producing drug-loaded devices that consist of filament preparation
followed by 3D printing using FFF 3D printers has been explored intensively. However, this approach
has some limitations due to the need for the HME step to prepare filaments with the intended diameter.
Additionally, the shelf-life stability of such filaments is crucial for a smooth feeding performance and
consistent quality for the end-product. Some filaments are hygroscopic, which might negatively affect
their mechanical properties. Thus, another trend was introduced by a few research groups in which
the raw materials were directly fed into the printer. Recently, research groups such as Fanous et al. [75],
Ong et al. [76], and Goyanes et al. [77] discussed this approach. However, it is critical to understand
that raw material homogeneity is the most important factor in this process. Fanous et al. [75] used
a piston extruder in the 3D printing process that does not offer any mixing abilities during printing.
On the other hand, Ong et al. [76] and Goyanes et al. [77] used a single screw extruder that has
minimal capacity for mixing and homogenizing. Moreover, Justino Netto and Silveira [78] illustrated a
prototype of a 3D printer fitted with a double screw extruder. However, testing and validating the
suitability of such extrusion systems are still needed.
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